| |
Consumers are looking to improve their gut health and direct-to-consumer testing companies are investing in the opportunity. Discover key considerations and learn how to pick the best at-home fecal collection device in this free guide. Download Now.
|
|
Today's Big NewsJan 24, 2023 |
|
Phreesia Life Sciences surveyed more than 4,300 patients checking in for their doctors’ appointments to better understand their perceptions and
preferences around clinical trials. But what's the best way to reach them? View Infographic
|
|
| By Gabrielle Masson There's a time and a place for everything, and right now might be the time for venture debt as biotechs operate on razor-thin margins. |
|
|
|
By Nick Paul Taylor Finch Therapeutics is throwing in the towel. Shortly after getting its phase 3 clinical trial back on track, the microbiome biotech has decided to stop the study and seek to offload assets in the face of a frosty funding forecast and slow enrollment. |
By Max Bayer Johnson & Johnson continued to trim away at early-stage cancer prospects, culling a prostate and solid tumor asset, respectively. The decision comes as the company was quiet on the specific timing of looming 2023 readouts. |
Sponsored by Clarify Health We initiate a discussion focused on the relation of clinical trials and the need for geographical inclusion versus societal exclusivity. With some trial sites including only 20% of the disease population in the United States, innovation is needed. |
By Annalee Armstrong Cassava Sciences, which spent 2022 trying to prove the integrity of its Alzheimer’s disease program, is trumpeting a phase 2 win for simufilam in an open-label study—but investors aren’t convinced. |
By James Waldron An SEC filing released this week gives far greater insight into the dealings that went into the first major M&A deal of 2023 between AstraZeneca and CinCor. |
By Nick Paul Taylor The shiver of sharks circling Spectrum Pharmaceuticals is growing bigger and bigger. Another law firm joined the pack on Tuesday, filing a class-action suit that accused the biotech of misrepresenting clinical trial data and failing to enroll patients in a confirmatory phase 3 study. |
By Helen Floersh Jennifer Doudna, Ph.D., who was awarded a Nobel Prize in Chemistry for developing CRISPR technology, foresees a bright future for the tech—and potential sticker shock for patients, unless manufacturing costs come down. |
By Andrea Park Prosecutors have asked a judge not to allow convicted Theranos founder Elizabeth Holmes to stay out of prison during her upcoming appeal process, citing an instance ahead of her sentencing last year where she appeared to be preparing to flee the U.S. |
By Heather Landi Amazon's pharmacy business is rolling out a new subscription service that enables Prime members to get unlimited generic medications for a flat fee of $5 a month. |
By Nick Paul Taylor Midatech Pharma’s plans to pivot past its cash crunch have come unstuck. After securing financing and striking a deal to buy Bioasis Technologies, Midatech put its plans to a vote—only for investors to shoot down the proposals and leave the drug delivery specialist with weeks to find an alternative option. |
By Zoey Becker Shooting for the stars, up-and-coming oncology player Bayer is starting 2023 riding high on Nubeqa's recent progress. The company aims to pull in $10 billion from oncology products by 2030. |
By Frank Diamond Officially, about 1.1 million individuals died from COVID-19 so far in the U.S. Researchers argue the number might be much, much higher because of flaws in recording the cause of death. |
By Eric Sagonowsky As the biopharma industry moves beyond its groundbreaking pandemic response, we're looking for leaders with ideas that'll shape the future of the industry. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
March 14-15, 2023 | San Francisco, CA Be in the room with the life sciences industry leaders to forge new connections & take advantage of in-person networking opportunities. Register now to be in the room for this amazing networking opportunity!
|
|
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
